Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.

Abstract: Disclosed is a method for preparing a compound of Formula 1 wherein Q and Z are as defined in the disclosure comprising distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a wherein M1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water.

Abstract: This invention relates to fluoroalkyl and chlorofluoroalkyl benzenes with relatively high boiling points, having zero ozone depletion potential and low global warming potential. This invention also relates to the preparation of such fluoroalkyl and chlorofluoroalkyl benzenes. These materials can be used as reaction and heat transfer media, cleaning agents and as intermediates for biologically active materials.

Abstract: A compound of the general formula X-[Q-W—(CH?CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8. The compounds find use in the conjugation of biological molecules.

Abstract: The present invention relates to chemical total synthesis methods of six novel protein tyrosine phosphatase-1B (PTP1B) inhibitors and application of the inhibitors in the preparation of medicaments for treating type 2 diabetes mellitus (T2DM). The PTP1B inhibitors use one or more of the six compounds represented by the structural formulae 1, 2, 3, 4, 5 and 6, as active components. The compounds can enhance the sensitivity of an insulin receptor by inhibiting the activity of PTP1B, thereby having a favorable therapeutic effect on insulin-resistant T2DM.

Abstract: This invention relates to fluoroalkyl and chlorofluoroalkyl benzenes with relatively high boiling points, having zero ozone depletion potential and low global warming potential. This invention also relates to the preparation of such fluoroalkyl and chlorofluoroalkyl benzenes. These materials can be used as reaction and heat transfer media, cleaning agents and as intermediates for biologically active materials.

Abstract: Disclosed is a method for preparing a compound of Formula 1 wherein Q and Z are as defined in the disclosure comprising distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a wherein M1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water.

Abstract: The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.

Abstract: A composition comprising a polymer backbone and at least one side group, wherein the side group comprises a benzene ring-based chromophore comprising a ketone at the 1-position, a substituted or unsubstituted amino group at the 2-position, and an oxygen atom at the 3-position of the benzene ring. The chromophore is a kynurenine-based compound. Methods of making and using the composition are also provided. The composition can be used in an ophthalmic lens or device for protecting the retina by blocking UV rays and filtering violet rays.

Abstract: A compound of the general formula X-[Q-W—(CH?CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8. The compounds find use in the conjugation of biological molecules.

Abstract: Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN-COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an ?,?-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.

Abstract: Disclosed is a method for preparing a compound of Formula 1 wherein Q and Z are as defined in the disclosure comprising distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a wherein M1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water.

Abstract: The present disclosure features a strain-promoted [2+2+2] reaction that can be carried out under physiological conditions. In general, the reaction involves reacting a pi-electrophile with a low lying LUMO with a quadricyclane on a biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo and in vitro. The reaction is compatible with modification of living cells. In certain embodiments, the pi-electrophile can comprise a molecule of interest that is desired for delivery to a quadricyclane-containing biomolecule via [2+2+2] reaction.

Abstract: A method for producing acetophenone comprising: treating one or more alkylbenzenes comprising s-butylbenzene to produce a feed comprising phenol and acetophenone; separating a crude phenol stream from the feed under crude phenol separation conditions effective to produce a crude phenol heavies; and, separating an acetophenone stream directly from the crude phenol heavies under azeotropic distillation conditions.

Abstract: A method of forming a fluorinated molecular entity includes reacting in a reaction mixture an aromatic halide, copper, a fluoroalkyl group, and a ligand. The aromatic halide includes an aromatic group and a halogen substituent bonded to the aromatic group. The ligand includes at least one group-V donor selected from phosphorus and an amine. The overall molar ratio of copper to aromatic halide in the reaction mixture is from 0.2 to 3. The method further includes forming a fluoroalkylarene including the aromatic group and the fluoroalkyl group bonded to the aromatic group. A composition, which may be used in the method, consists essentially of copper, the fluoroalkyl group, and the ligand, where the molar ratio of copper to the fluoroalkyl group is approximately 1.

Abstract: An offset printing blanket cleaning liquid includes: a solvent having a dipole moment of about 1.7 or more but less than about 4.1 and having a ? covalent bond in a molecular skeleton thereof. Moreover, an ink composition includes: an organic material; and a solvent having a dipole moment of about 1.3 to about 3.0 both inclusive and having a ? covalent bond in a molecular skeleton thereof.

Abstract: The present invention relates to processes for the preparation of (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (Fingolimod) and pharmaceutically acceptable salts thereof, and intermediates formed in such processes.

Abstract: The present invention relates to methods of treating Ataxia-Telangiectasia (A-T) or Ataxia-telangiectasia like disorder (ATLD) with compounds such as tocotrienol quinones and tocotrienol hydroquinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Abstract: The present invention provides a novel compound for counteracting amine-based malodor in consumer, industrial and textile products.

Abstract: Methods for fluorinating organic compounds are described herein.

Abstract: Provided is a solvent for forming an alignment film capable of fabricating a liquid crystal alignment film having high quality, an improved imidization ratio, large surface anisotropy, and a strong anchoring force. The solvent for forming an alignment film including a polymer for a liquid crystal display includes the polymer of the alignment film including polyimide and a variable compound capable of changing a chemical structure for evaporating after imidizing and sintering, which is in a liquid state during a film-forming process of coating, imidizing, and sintering polyamic acid which is a precursor of polyimide.

Abstract: Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.

Abstract: Disclosed is a method for preparing a compound of Formula 1 wherein Q and Z are as defined in the disclosure comprising distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a wherein M1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water.

Abstract: A photoactive compound that is the Michael addition reaction product of an aziridine compound and a photoinitiator-functional (meth)acrylate is described. The compound can be used to crosslink (meth)acrylic polymers via a hydrogen abstracting or an alpha-cleavage mechanism.

Abstract: Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents.

Abstract: The invention relates to quinoid compounds and their use in semiconductive matrix materials, electronic and optoelectronic structural elements.

Abstract: Functionalized detonation nanodiamond particulates of the formula: wherein Ar is selected from the group consisting of: wherein R is selected from the group consisting of H, H3C—(CH2)n— and wherein n has a value of 0-10. Also provided is a process for functionalizing detonation nanodiamonds particulates.

Abstract: An aromatic polymer, containing a repeating unit represented by Formula (I), and having properties (A1) and (B1): (A1) the number average degree of polymerization of an acetylated product obtained by acetylation of the hydroxyl groups of the polymer is 3 or more, and (B1) at a wavelength where an absolute value of molar ellipticity (degree·cm?2·dmol?1) per mole of the repeating unit of the acetylated product in a circular dichroism spectrum of the acetylated product reaches maximum in a wavelength range of from 200 to 350 nm, the absolute value is 50,000 or more: wherein R represents a hydrocarbon, hydrocarbon-oxy, hydrocarbon-mercapto or hydrocarbon-amino group that may be substituted; the two R's may bind to each other to form a ring; and the repeating unit represented by Formula (I) has no symmetrical plane that has two binding sites and that is perpendicular for the benzene ring.

Abstract: Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN—COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an ?,?-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.

Abstract: The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae and pharmaceutically acceptable salts, amides, esters, and ethers thereof, wherein: Ar1, Ralk, —ORO, and -Q are as defined herein: The present invention also pertains to pharmaceutical compositions comprising such compounds. The compounds inhibit osteoclast survival, formation, and/or activity, and inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, and are useful in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

Abstract: Compounds of formula I Y is, for example, C3-C12alkylene, butenylene, butynylene, or C4-C12alkylene interrupted one or more times by non-consecutive —O— or —NR2—; R1 is a reactive group selected from OH, SH, NR3R4, —(CO)—OH, —(CO)—NH2, SO3H, —C(R5)?CR6R7, oxiranyl, —O—(CO)—NH—R8—NCO and —O—(CO)—R9—(CO)—X; R2 is hydrogen, C1-C4alkyl or C2-C4hydroxyalkyl; R3 and R4 are each independently of the other hydrogen, C1-C4alkyl or C2-C4hydroxyalkyl; R5, R6 and R7 are each independently of the others hydrogen or methyl; R8 is, for example, linear or branched C4-C12alkylene, or phenylene; R9 is, for example, linear or branched C1-C16alkylene, —CH?CH—, —CH?CH—CH2—, C6-cycloalkylene, phenylene or naphthylene; and X, X1 and X2 are each independently of the others OH, Cl, OCH3 or OC2H5; are suitable as photoinitiators that can be incorporated in a formulation to be cured.

Abstract: The present invention relates to the use of end groups Y, where Y stands for (formula I), where Rf stands for CF3—(CH2)r—, CF3—(CH2)r—O—, CF3—(CH2)r—S—, CF3CF2—S—, SF5—(CH2)r—, [CF3—(CH2)r]2N—, [CF3—(CH2)r]NH— or (CF3)2N—(CH2)r—, B stands for a single bond, O, NH, NR, CH2, C(O)—O, C(O), S, CH2—O, O—C(O), N—C(O), C(O)—N, O—C(O)—N, N—C(O)—N, O—SO2 or SO2—O, R stands for alkyl having 1 to 4 C atoms, b stands for 0 or 1 and c stands for 0 or 1, q stands for 0 or 1, where at least one radical from b and q stands for 1, and r stands for 0, 1, 2, 3, 4 or 5, as end group in surface-active compounds, to corresponding novel compounds, and to processes for the preparation of these compounds.

Abstract: This invention discloses (20S)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20S)-23,23-difluoro-1?-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

Abstract: This invention discloses (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20R)-23,23-difluoro-1 ?-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

Abstract: The present invention relates to a computer-assisted method of a designing of a tubulin inhibitor comprising: a) determining an interaction between a tubulin protein and a chemical known to bind the tubulin protein by evaluating a binding of the tubulin protein to the chemical known to bind the tubulin protein; b) based on the interaction, designing a candidate tubulin inhibitor; c) determining an interaction between the tubulin protein and the candidate tubulin inhibitor by evaluating a binding of the tubulin protein to the candidate tubulin inhibitor; and d) concluding that the candidate tubulin inhibitor inhibits the tubulin protein wherein the conclusion is based on the interaction of step c). The invention also provides compositions and methods of treatment of diseases with the candidate tubulin inhibitors.

Abstract: The liquid, uncrosslinked, UV-curable Michael addition resins and blends of the present invention exhibit performance properties that make them very effective coating materials and these properties can be modified greatly depending upon composition. Michael donors and acceptors can be constructed from Type I and/or Type II photoinitiators and can be included in the coating compositions disclosed to make UV-curable coatings with extraordinary photoreactivity and properties. Resins can be produced that show excellent adhesion to metals, plastics, wood, paper and glass. They exhibit wide ranges of hardness, toughness, flexibility, tensile strength, stain resistance, scratch resistance, impact resistance, solvent resistance, etc. Almost any desired coating performance parameter can be attained by proper selection of raw material building blocks.

Abstract: The present invention relates to new crystalline molecular sieve SSZ-74 prepared using a hexamethylene-1,6-bis-(N-methyl-N pyrrolidinium) dication as a structure-directing agent, methods for synthesizing SSZ-74 and processes employing SSZ-74 in a catalyst.

Abstract: This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or blocking antibodies specific for the peptides, are also described, as are pharmaceutical compositions comprising the modulatory agents, and methods for using the modulatory agents to diagnose or treat patients.

Abstract: This invention relates to the compositions and processes for preparing 2,3,3?,4?-tetramethylbenzophenone and asymmetrical dianhydrides such as 2,3,3?,4? benzophenone dianhydride (a-BTDA), and 3,4?-(hexafluoroisopropylidene)diphthalic anhydride (a-6FDA). a-BTDA is prepared by Suzuki coupling with catalysts from a mixed anhydride of 3,4-dimethylbenzoic acid and 2,3-dimethylbenzoic acid with a respective 2,3-dimethylphenylboronic acid and 3,4-dimethyl phenylboronic acid to form 2,3,3?,4?-tetramethylbenzophenone which is oxidized to 2,3,3?,4?-benzophenonetetracarboxylic acid followed by cyclodehydration to obtain a-BTDA. The a-6FDA was prepared by nucleophilic trifluoromethylation of 2,3,3?,4?-tetramethylbenzophenone with trifluoromethyltrimethylsilane to form 3,4?-(trifluoromethylmethanol) bis(o-xylene) which is converted to 3,4?-(hexafluoroisopropylidene-bis(o-xylene). The 3,4?-(hexafluoroisopropylidene)-bis(o-xylene) is oxidized to the corresponding tetraacid followed by cyclodehydration to yield a-6FDA.

Abstract: A wax-tethered photoinitiator that is a photoinitiator compound including a wax chain therein, wherein the photoinitiator compound is activated by ultraviolet radiation, and method of making the same is described. The wax-tethered photoinitiator may be used in a curable wax composition for incorporation into a toner. The wax-tethered photoinitiator exhibits an affinity for the wax phase, thereby insuring its presence in the wax for the initiation of curing thereof.

Abstract: The use of 2-methyl-benzoic acid methyl ester as a fragrance chemical, suitable for use in creating fragrance, and scents in items such as perfumes, colognes and personal care products is disclosed.

Abstract: The invention relates to a process for preparing fluorinated acetophenones from fluorinated aryl compounds in the presence of N-hydroxyphthalimide and the use thereof.

Abstract: According to one aspect of the invention, there is provided the use of an organic ionic liquid in a zeolite-catalysed process, for example an acylation, alkylation, isomerisation or hydrocracking process in which zeolites act as catalysts or catalyst precursors, especially Friedel-Crafts alkylation and acylation procedures.

Abstract: The present invention pertains to compounds of the following formula: (1) wherein: RALK is primary or secondary aliphatic saturated C2-6alkyl; each of RB2, RB3, RB4, and RB5 is independently —H, —OH, or —OMe; each of R1 and R2 is independently: —H, optionally substituted C1-4alkyl, or optionally substituted C5-20aryl; RA3 is —H, —OH, —OC(?O)RE, —OS(?O)2OH, or —OP(?O)(OH)2; RE is: —H, optionally substituted C1-6alkyl, optionally substituted C3-20heterocyclyl, or optionally substituted C5-20aryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof.

Abstract: The present invention relates to new molecular sieve SSZ-71 prepared using a N-benzyl-1,4-diazabicyclo[2.2.2]octane cation as a structure-directing agent, methods for synthesizing SSZ-71 and processes employing SSZ-71 in a catalyst.

Abstract: An ecofriendly process for acylation of an alkylated benzene derivative has increased selectively towards para position and comprises a step of reacting the alkylated benzene derivative with an acylating agent in the presence of nitrobenzene, dichlorobenze, dimethylsulfolane, and/or benzotrile, and a crystalline alumino silicate catalyst having general formula M2/nO.Al2O3.xSiO2.wH2O, wherein M is an alkali cation, a rare earth cation, and/or a proton, wherein the Si/Al ratio is in the range of 5.5 to 20, wherein the step of reacting is performed at temperature between 80° to 140° C. for 5 to 25 hours. In a further step, the solid catalyst is separated from the reaction mixture of step, and in yet another step, the acylated alkyl benzene derivative is separated from the mixture.

Abstract: The present invention relates to new crystalline molecular sieve SSZ-70 prepared using a N,N?-diisopropyl imidazolium cation as a structure-directing agent, methods for synthesizing SSZ-70 and processes employing SSZ-70 in a catalyst.

Abstract: The invention relates to new antibiotics designated Cyan-416A, Cyan 416B, Cyan-416C, Cyan-416D and Cyan-416E to their production by fermentation of Acremonium sp. NRRL 30631 to methods for recovery and concentration from the crude solutions, and to a process for purification and to semisynthetic ethers of Cyan-416B.

Abstract: The present invention provides a new fluorine-containing acetophenone derivative useful as a photo initiator, and a surface layer material containing the fluorine-containing acetophenone derivative. The present invention provides inexpensively an article with a hard coat excellent in anti-staining property, lubricity, scratch resistance and abrasion resistance, and provides a method for forming the hard coat. A fluorine-containing acetophenone derivative represented by the following general formula (I): wherein R1, R2 and R3 each independently represent an organic group other than aryl group, a hydrogen atom, a halogen atom or a hydroxyl group, provided that the following case does not take place: all of R1, R2 and R3 are simultaneously hydrogen atoms; and any two of R1, R2 and R3 may be linked to each other to form a ring, and R4 represents a fluorine-containing organic group.

Abstract: Functionalized nanoscale carbon fibers and tubes of the formula: wherein Ar is selected from the group consisting of: wherein R is selected from the group consisting of H, H3C—(CH2)n— and wherein n has a value of 0–10. Also provided is a process for functionalizing nanoscale carbon fibers or tubes.